Meeting
2022 ASCO Annual Meeting
Trends in treatment patterns associated with small cell lung cancer in a U.S. Medicare population.
Authors
Robert A. Ramirez
Vanderbilt University Medical Center, Nashville, TN
Robert A. Ramirez , Marley Boyd , Paul Cockrum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8584)
DOI
10.1200/JCO.2022.40.16_suppl.8584
Abstract #
8584
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
First Author: Yosuke Kawashima
Poster
2023 ASCO Genitourinary Cancers Symposium
Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer.
First Author: Jean H. Hoffman-Censits
Poster
2015 Gastrointestinal Cancers Symposium
Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma.
First Author: Takayuki Ando
Poster
2014 ASCO Annual Meeting
Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.
First Author: Morten Mau-Soerensen